312 related articles for article (PubMed ID: 15700745)
1. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk.
Rallis E; Nasiopoulou A; Kouskoukis C; Koumantaki E
Drugs Exp Clin Res; 2004; 30(5-6):191-5. PubMed ID: 15700745
[TBL] [Abstract][Full Text] [Related]
2. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study.
Ozden MG; Tekin NS; Ilter N; Ankarali H
Am J Clin Dermatol; 2010; 11(1):51-4. PubMed ID: 20000875
[TBL] [Abstract][Full Text] [Related]
3. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
5. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.
Cicek D; Kandi B; Bakar S; Turgut D
J Dermatolog Treat; 2009; 20(6):344-9. PubMed ID: 19954391
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
7. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV.
de Moraes AP; de Arruda EA; Vitoriano MA; de Moraes Filho MO; Bezerra FA; de Magalhães Holanda E; de Moraes ME
J Eur Acad Dermatol Venereol; 2007 May; 21(5):596-601. PubMed ID: 17447972
[TBL] [Abstract][Full Text] [Related]
8. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea.
Karabulut AA; Izol Serel B; Eksioglu HM
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):729-34. PubMed ID: 18328059
[TBL] [Abstract][Full Text] [Related]
9. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
Chu CY
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
[TBL] [Abstract][Full Text] [Related]
10. Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile.
Tatlican S; Eren C; Eskioglu F
J Dermatolog Treat; 2009; 20(4):198-202. PubMed ID: 19255921
[TBL] [Abstract][Full Text] [Related]
11. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis.
Koc E; Arca E; Kose O; Akar A
J Dermatolog Treat; 2009; 20(1):4-9. PubMed ID: 18677657
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
[TBL] [Abstract][Full Text] [Related]
13. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck.
Mensing CO; Mensing CH; Mensing H
Int J Dermatol; 2008 Sep; 47(9):960-4. PubMed ID: 18937664
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
15. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
Abramovits W; Fleischer AB; Jaracz E; Breneman D
J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
[TBL] [Abstract][Full Text] [Related]
16. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.
Elewski B
Clin Dermatol; 2009; 27(6 Suppl):S48-53. PubMed ID: 19878781
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
18. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
19. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
20. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis.
Meshkinpour A; Sun J; Weinstein G
J Am Acad Dermatol; 2003 Jul; 49(1):145-7. PubMed ID: 12833030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
